Aratana Therapeutics Inc (NASDAQ:PETX) – Stock analysts at William Blair lifted their Q1 2019 earnings per share estimates for Aratana Therapeutics in a research report issued on Wednesday, March 13th. William Blair analyst J. Kreger now anticipates that the biopharmaceutical company will post earnings per share of ($0.09) for the quarter, up from their previous estimate of ($0.10). William Blair has a “Market Perform” rating and a $4.14 price target on the stock. William Blair also issued estimates for Aratana Therapeutics’ Q2 2019 earnings at ($0.09) EPS, Q3 2019 earnings at ($0.06) EPS, Q4 2019 earnings at ($0.04) EPS and FY2019 earnings at ($0.29) EPS.
Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.06). The company had revenue of $4.91 million for the quarter, compared to the consensus estimate of $6.53 million. Aratana Therapeutics had a negative return on equity of 14.84% and a negative net margin of 41.57%.
Shares of PETX stock opened at $3.80 on Friday. The company has a market capitalization of $184.76 million, a price-to-earnings ratio of -11.88 and a beta of 1.38. The company has a quick ratio of 2.70, a current ratio of 3.17 and a debt-to-equity ratio of 0.02. Aratana Therapeutics has a fifty-two week low of $3.30 and a fifty-two week high of $7.16.
Several large investors have recently made changes to their positions in PETX. Northern Trust Corp boosted its position in shares of Aratana Therapeutics by 7.2% during the second quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock valued at $2,082,000 after buying an additional 32,773 shares during the last quarter. Bank of Montreal Can boosted its position in Aratana Therapeutics by 152.9% in the third quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 31,053 shares during the last quarter. Acadian Asset Management LLC boosted its position in Aratana Therapeutics by 69.8% in the third quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock worth $1,137,000 after purchasing an additional 80,064 shares during the last quarter. Wells Fargo & Company MN boosted its position in Aratana Therapeutics by 8.9% in the third quarter. Wells Fargo & Company MN now owns 747,074 shares of the biopharmaceutical company’s stock worth $4,362,000 after purchasing an additional 61,315 shares during the last quarter. Finally, BlackRock Inc. boosted its position in Aratana Therapeutics by 2.7% in the third quarter. BlackRock Inc. now owns 3,439,584 shares of the biopharmaceutical company’s stock worth $20,087,000 after purchasing an additional 91,344 shares during the last quarter. 68.64% of the stock is currently owned by institutional investors.
In other news, insider Peter Steven St sold 46,094 shares of the business’s stock in a transaction that occurred on Monday, December 17th. The stock was sold at an average price of $5.85, for a total transaction of $269,649.90. Following the completion of the sale, the insider now owns 516,626 shares in the company, valued at $3,022,262.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 5.30% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
Recommended Story: Derivative
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.